Biomarker analysis reveals several potential treatment targets in subtype of anal cancer

The researchers analyzed 212 tumor samples using three types of genetic profiling: gene sequencing (Sanger or next-generation sequencing), protein expression (immunohistochemistry, or IHC) and gene amplification (CISH or FISH assays). For 80.2% of the samples, tissue from a metastatic site was also analyzed.

The team found evidence of significant IHC overexpression in several genes: MRP1, in 97.6% of the analyzed samples; EGFR, 89.7%; TOPO1, 68.3%; MGMT, 67.2%; and PTEN, 46.9%. EGFR and HER2 were amplified in 7.4% and 1.8% of the cases, respectively. Additionally, high mutation rates were seen in biomarkers associated with the PIK3CA/Akt pathway (PIK3CA, FBXW7, PTEN and Akt1), and PIK3CA exon 9 mutations were detected in 75% of all PIK3CA mutations.

"Our findings are exciting, as we were able to identify several potential biomarkers that can be targeted with existing therapies. Drugs that target the PI3 kinase pathway and ErbB-family receptors may prove to be particularly effective in these cancers, for instance anti-EGFR agents or newer pan-HER inhibitors," says Dr. Boland, an Assistant Professor of Oncology in the Department of Medicine at Roswell Park and the study's first and presenting author. "Additionally, our results suggest that this approach may also be similarly effective in identifying targets in other tumors of viral origin."

The study, "Comprehensive multiplatform biomarker analysis of 212 anal squamous cell carcinomas," is abstract 3519 and will be presented on board no. 11 during the Gastrointestinal (Colorectal) Cancer poster session Monday, June 1.